Biogen Inc.
147.86-1.27 (-0.85%)
Oct 29, 4:00:00 PM EDT · NasdaqGS · BIIB · USD
Key Stats
Market Cap
21.68BP/E (TTM)
14.15Basic EPS (TTM)
10.45Dividend Yield
0%Recent Filings
8-K
Biogen's Q3 R&D charge
Biogen disclosed an expected $2 million pre-tax charge for acquired in-process research and development, upfront, and milestone expenses in Q3 2025, stemming from collaboration and license agreements. This hit will trim GAAP and non-GAAP net income per diluted share by $0.01. Preliminary results await finalization. Uncertainty clouds these costs.
8-K
Biogen boosts Q2 revenue, guidance
Biogen reported Q2 2025 revenue of $2.6 billion, up 7% year-over-year, fueled by robust growth in launch products like LEQEMBI ($160 million global in-market sales) and ZURZUVAE ($46 million), while MS revenue dipped 4% amid competitive pressures. Non-GAAP diluted EPS hit $5.47, up 4%, despite $47 million in acquired IPR&D costs. The company raised full-year 2025 guidance to $15.50-$16.00 Non-GAAP EPS and flat revenue at constant currency. Pipeline advances shine, yet ex-U.S. MS headwinds loom.
10-Q
Q2 FY2025 results
Biogen's Q2 revenue climbed 7.3% year-over-year to $2.6B, fueled by Alzheimer's collaboration gains from LEQEMBI's ramp-up and steady anti-CD20 royalties, while product sales dipped 1.1% amid MS erosion. Gross margins held firm despite higher costs from SKYCLARYS amortization, but R&D spend fell 21.1% on efficiency drives, lifting operating income 6.4% to $744M and diluted EPS 8.3% to $4.33—derived from net income of $635M over 146.7M shares, with no anti-dilution flags. Cash flow from operations slowed to $420M YTD on tax timing, yet $2.8B cash bolsters liquidity against $6.3B debt, including fresh 2025 notes; free cash flow not disclosed in the 10-Q. HI-Bio integration advances felzartamab's Phase 3 trials, eyeing immunology synergies. Biosimilar competition pressures pricing in Europe.
8-K
Biogen's Q2 charge preview
Biogen disclosed an anticipated $46 million pre-tax charge for acquired in-process research and development, upfront, and milestone expenses in Q2 2025, stemming from collaboration and license agreements. This hit will dent GAAP and non-GAAP diluted EPS by $0.26. Preliminary figures await finalization amid closing procedures. Risks could alter outcomes materially.
8-K
Biogen annual meeting results
Biogen's stockholders, at the June 17, 2025 annual meeting, elected all eleven board nominees for one-year terms, including strong support for new directors Lloyd Minor and Menelas Pangalos. They ratified PricewaterhouseCoopers as auditors for 2025 and approved executive compensation on an advisory basis, though with notable opposition at 32%. Board continuity holds firm. Yet dissent lingers on pay.
IPO
Website
Employees
Sector
Industry
ABBV
AbbVie Inc.
225.14-2.40
AMGN
Amgen Inc.
291.77-0.32
AZN
Astrazeneca PLC
82.23-0.38
BHVN
Biohaven Ltd.
18.11+0.91
BMRN
BioMarin Pharmaceutical Inc.
51.86-1.63
BMY
Bristol-Myers Squibb Company
42.60-0.22
LLY
Eli Lilly and Company
813.53-6.57
PFE
Pfizer, Inc.
24.29-0.21
REGN
Regeneron Pharmaceuticals, Inc.
652.91-1.57
TEVA
Teva Pharmaceutical Industries
20.23+0.45